Improving the immune response of stem cells to treat graft-versus-host disease.
Official title: Mechanical programming to enhance the immunosuppressive function of mesenchymal stem cells for the treatment of graft-versus-host disease.
Funded at Johns Hopkins University · NIH-10905160 · Data updated 2026-11-12
This study is looking at ways to make special stem cells better at helping people with graft-versus-host disease (GvHD) by creating a more natural environment for them to grow, which could lead to improved treatments for patients who have had stem cell transplants.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 7, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $393,953 |
| NIH project number | 1R56HL169764-01 |
| Project ID | NIH-10905160 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who have undergone stem cell transplants and are at risk of developing graft-versus-host disease.
✕Less likely to help
Patients who do not have graft-versus-host disease or are not undergoing stem cell transplants may not benefit from this research.
What this research studies
This research focuses on enhancing the immunosuppressive abilities of mesenchymal stem cells (MSCs) to better treat graft-versus-host disease (GvHD). The approach involves optimizing the mechanical environment in which these stem cells are produced, as this can significantly influence their effectiveness. By using a specialized hydrogel system that mimics the natural conditions of the body, the researchers aim to create MSCs that are more potent in regulating immune responses. This could lead to more effective therapies for patients suffering from GvHD, a serious complication often seen in patients undergoing stem cell transplants.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with graft-versus-host disease, improving their recovery and quality of life.
How similar studies have gone: Previous research has shown promise in using mechanical cues to enhance stem cell therapies, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Gu, Luo — Johns Hopkins University
- Study coordinator: Gu, Luo
Related research
Other NIH-funded projects on the same topics.
-
Targeting early oral GVHD to improve mouth health after stem cell transplant
A study at UW–Madison will explore why some transplant patients develop painful oral GVHD and test ideas to prevent and lessen mouth-related problems.
-
Microbiome-based therapy for treatment-refractory GVHD after stem cell transplant
A microbiome-based therapy is being developed to help people who have graft-versus-host disease that doesn’t respond to standard treatments after a stem cell transplant.
-
Role of altered mitochondria in preventing GVHD after stem cell transplant
This NIH grant explores how damaged mitochondria released during pre-transplant conditioning may trigger graft-versus-host disease and tests ways to fix mitochondrial dynamics to prevent GVHD.
-
Fecal transplant plus fiber to treat graft-versus-host disease after blood stem cell transplant
A study to see if giving fecal transplant along with dietary fiber helps gut health and reduces complications in patients who have received a stem cell transplant and developed graft-versus-host disease.
-
Using medium-chain fatty acids and a fat-sensing receptor to treat chronic graft-versus-host disease
This project looks at whether changing medium‑chain fatty acids or blocking a fat sensor called GPR84 can help people with chronic graft‑versus‑host disease after a bone marrow/stem cell transplant.
-
Microbiome-based oral therapy for gut GVHD after stem cell transplant
Researchers are testing an oral live Biotherapeutic Product to help the gut microbiome improve graft-versus-host disease after stem cell transplant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.